| Inhibitor |
Griffithsin (nM) |
Dose reduction |
P<0.05 |
Inhibitor |
Dose reduction |
P <0.05 |
| Alone |
Combi |
Alone |
Combi |
| Reverse transcriptase inhibitors |
| efavirenz (nM) |
0.094 ± 0.014 |
0.019 ± 0.003 |
5.1 |
0.002 |
9.7 ± 2.1 |
4.8 ± 0.7 |
2.0 |
0.069 |
| tenofovir (μM) |
0.069 ± 0.020 |
0.064 ± 0.009 |
1.1 |
0.860 |
34.7 ± 4.0 |
0.66 ± 0.09 |
52.8 |
0.001 |
| UC-781 (nM) |
0.081 ± 0.009 |
0.024 ± 0.008 |
3.3 |
0.003 |
3.7 ± 1.1 |
1.5 ± 0.5 |
2.5 |
0.104 |
| etravirine (nM) |
0.074 ± 0.015 |
0.017 ± 0.005 |
4.4 |
0.010 |
1.4 ± 0.5 |
0.79 ± 0.22 |
1.8 |
0.285 |
| Integrase inhibitors |
| raltegravir (nM) |
0.093 ± 0.015 |
0.060 ± 0.019 |
1.5 |
0.213 |
18.7 ± 4.1 |
1.2 ± 0.4 |
15.2 |
0.003 |
| elvitegravir (nM) |
0.101 ± 0.015 |
0.028 ± 0.011 |
3.6 |
0.008 |
3.7 ± 1.1 |
1.7 ± 1.1 |
2.2 |
0.252 |
| Protease inhibitors |
| saquinavir (μM) |
0.080 ± 0.022 |
0.054 ± 0.004 |
1.5 |
0.322 |
>14.9 |
>14.9 |
|
|
aMean EC50s ± SEM up to 5 independent experiments.
P<0.05 (unpaired T-test), compared to single drug treatment. |
